CoChat

The DOI matches its Crossref record; 48 of the 54 references it cites were found in a registry or an index; 51 of the 94 sources its claims cite were checked for support.

Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis

Open access
Rennwald, Andri, Hengartner, Michael P. · 2025 · Epidemiology and Psychiatric Sciences

Abstract

Aims: The literature on persistent antidepressant withdrawal symptoms is sparse. This systematic review is the first to examine the prevalence, duration, severity, risk/protective factors and treatment strategies for post-acute withdrawal syndrome (PAWS) following the discontinuation of antidepressant medications. Methods: We searched PubMed, Web of Science and PsycInfo, focusing on newer-generation antidepressants. The electronic database search was complemented with handsearching reference lists of pivotal studies. We included original studies in adults reporting on PAWS and providing data about epidemiology and clinical management of withdrawal symptoms persisting for at least 6 weeks. Results: The literature search yielded 1286 results, with 26 records assessed for eligibility, and seven studies fulfilled our selection criteria. Prevalence data were sparse, with one small cohort study reporting a 15% prevalence rate for PAWS in patients with panic disorder and agoraphobia. The duration of PAWS varied considerably across studies, ranging from 1.5 to 166 months. Long-term paroxetine use emerged as a potential risk factor for the development of PAWS. There was no reliable evidence to support the effectiveness of various treatment strategies, including the reinstatement of antidepressant medication, the use of benzodiazepines and the provision of cognitive-behavioral therapy. Conclusions: The current evidence on PAWS is sparse and predominantly of low certainty. The presence of withdrawal symptoms, lasting several months and possibly even years in some patients, underscores the need for further research with rigorous methodology. Large prospective cohort studies are needed to assess the epidemiology of PAWS, while randomized controlled trials are quired to test the efficacy of clinical interventions to treat PAWS. PROSPERO registration: CRD42023461793

Overview

CoChat Summary

TL;DR

This systematic review with meta-narrative synthesis found only seven studies on post-acute withdrawal syndrome (PAWS) after stopping newer-generation antidepressants, with sparse and low-certainty evidence. Persistent withdrawal symptoms appear to exist and can last months to years, but prevalence, risk factors, and effective treatments remain poorly established.

Key findings

  • Only one included study reported prevalence: 3 of 20 patients (15%) with panic disorder and agoraphobia developed PAWS after slow tapering, all after long-term paroxetine use.
  • Duration estimates varied widely, from about 1.5 months to 166 months; one online self-report analysis reported a mean duration of 2.5 years (range 0.1–6 years), and another reported 5–166 months (mean 37, median 26 months).
  • In a large RCT of 478 primary care patients, those discontinuing antidepressants reported significantly more withdrawal symptoms than maintained patients at 12 weeks (3.1 vs. 1.3), 26 weeks (1.9 vs. 1.4), and 39 weeks (1.7 vs. 0.8).
  • Treatment evidence was unreliable: reinstatement resolved self-reported PAWS in 9 of 19 persons (47%) who attempted it, while other drugs including benzodiazepines, pregabalin, or propranolol gave at least some benefit in only 6 of 33 persons (18%); no intervention was tested in a clinical trial.

Methods

  • Systematic review pre-registered on PROSPERO (CRD42023461793), conducted per PRISMA and RAMSES, searching PubMed, Web of Science, and PsycInfo from inception to January 2024, plus handsearching and ClinicalTrials.gov.
  • Included original adult studies reporting PAWS or persistent/protracted withdrawal symptoms lasting at least 6 weeks after discontinuation of SSRIs, SNRIs, or other newer-generation monoaminergic antidepressants.
  • The search yielded 1286 results; after screening, 7 studies met criteria. Because meta-analysis was not possible, a meta-narrative synthesis was performed, with risk of bias rated using RoB-PrevMH.

Limitations

  • The paper states that evidence is sparse and predominantly of low certainty, with most studies rated high risk of bias in at least two of three domains; three studies relied on online self-reports from peer-support groups, and one was a single case report.
  • The paper states that the only prevalence estimate came from a small single-clinic cohort of 20 patients with panic disorder and agoraphobia, limiting generalizability, and that the large RCT could not provide prevalence rates because requests for additional data were declined.
  • The paper states that no treatment strategy was tested in a clinical trial and observational studies had no control group; evident from the text, the included studies were highly heterogeneous in design, populations, and outcome assessment, preventing formal meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s204579602500023x

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. PRISMA study selection flow chart.
Figure 1. PRISMA study selection flow chart.CC BY · PubMed Central

Verification

Claims the paper makes

42 Valid · 1 Not valid · 18 Not checked · 33 Own results and interpretations

44 more claims · 19 with their cited sources checked

Create a free account to see all 94 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 54 references

Cited by

See all 8

Metadata

Authors
Rennwald, A., & Hengartner, M. P.
Affiliations
  • ZHAW Zurich University of Applied Sciences (CH)
  • Kalaidos University of Applied Sciences (CH)
Corresponding author
Rennwald, Andri
Venue
Epidemiology and Psychiatric Sciences
Published
2025
Volume
34
Pages
e29-e29
ISSN
  • 2045-7960 (ISSN-L)
  • 2045-7979
OpenAlex
W4410321753
Cited by
8
References
54
Citations by year
2026: 5 · 2025: 3
FWCI
1.07
Type
journal article
Language
en
Open access
Locations
  • Epidemiology and Psychiatric Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Parrotia-Stiftung
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
antidepressant discontinuation, paroxetine, panic disorder, agoraphobia, benzodiazepines, cognitive behavioral therapy, risk factors, prevalence
MeSH terms
Antidepressive Agents, Humans, Risk Factors, Substance Withdrawal Syndrome, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis. https://app.cochat.ai/papers/10.1017/s204579602500023x
The paper
Rennwald, A., & Hengartner, M. P. (2025). Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s204579602500023x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.